X0206 3 2020-07-15 0 0001812364 Relay Therapeutics, Inc. RLAY 0001817110 Picularium, LLC 1166 AVENUE OF THE AMERICAS, 9TH FLOOR NEW YORK NY 10036 0 0 1 0 0001023870 SHAW DAVID E 120 WEST 45TH STREET, 39TH FLOOR NEW YORK NY 10036 0 0 1 0 Series A Preferred Stock, $0.001 par value per share Common Stock, $0.001 par value per share 9999999 D Series C Preferred Stock, $0.001 par value per share Common Stock, $0.001 par value per share 1651471 D Each share of Relay Therapeutics, Inc. ("Issuer") Series A Preferred Stock, $0.001 par value per share, is convertible into shares of Issuer Common Stock, $0.001 par value per share ("Common Stock"), at any time at the option of the holder. Shares of Series A Preferred Stock will automatically convert into shares of the Common Stock upon the closing of the Issuer's initial public offering of Common Stock. The current conversion rate is .281617 of a share of Common Stock for each share of Series A Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. Each share of Issuer Series C Preferred Stock, $0.001 par value per share, is convertible into shares of Common Stock at any time at the option of the holder. Shares of Series C Preferred Stock will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock. The current conversion rate is .2985366 of a share of Common Stock for each share of Series C Preferred Stock (reflecting a one-for-3.55092 reverse stock split effected on July 8, 2020). The shares had no expiration date. David E. Shaw is President and sole shareholder of D. E. Shaw & Co., II, Inc., which is the sole member of D. E. Shaw Technology Development, LLC, which is the managing member of D. E Shaw Research, LLC, which is the sole member and manager of Picularium, LLC. David E. Shaw disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, if any. PICULARIUM, LLC, A Delaware limited liability company, By: D.E. Shaw Research, LLC, its manager, By: /s/ David E. Shaw, Name: David E. Shaw, Title: Authorized Signatory 2020-07-15 /s/ David E. Shaw, David E. Shaw 2020-07-15